TradeFlare's AI research teams analysed MIRM on 7 market nights between May 21, 2026 and July 27, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| July 27, 2026 | BUY | $113.03 | — / — | -8.4% | -15.3% | Positive clinical trial data for zilurgisertib and volixibat. |
| June 26, 2026 | BUY | $117.28 | $137.39 / $99.69 | -1.5% | -7.7% | The stock is near its 52-week high with strong bullish momentum, suggesting a short-to-medium term upward trend. |
| May 28, 2026 | BUY | $97.33 | $111.93 / $82.75 | -7.1% | +24.3% | The bullish fundamental and sentiment signals, combined with a technical pullback, suggest a medium-term upward trend. |
| May 27, 2026 | BUY | $98.90 | — / — | -5.7% | +20.5% | The stock is currently in a neutral market regime with mixed signals, and the risk profile requires careful consideration. |
| May 26, 2026 | BUY | $98.62 | — / — | -6.8% | +16.2% | The current market regime is neutral, and while MIRM has bullish fundamental and sentiment signals, the technicals are neutral and the risk profile is high, requiring a clearer technical setup for a b |
| May 25, 2026 | HOLD | $98.62 | — / — | -6.8% | +16.2% | Continued strong revenue growth from rare liver disease therapies. |
| May 21, 2026 | HOLD | $96.95 | — / — | +0.8% | +7.0% | Continued positive news flow from clinical trial data for volixibat. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.